Febrile seizure during treatment with methylphenidate

Kensuke Miyazaki

doi:10.5234/cnpt.11.51

Clinical Neuropsychopharmacology and Therapeutics

Online ISSN : 1884-8826
ISSN-L : 1884-8826

Case Report

Febrile seizure during treatment with methylphenidate

Kensuke Miyazaki

Author information

Keywords: Attention deficit hyperactivity disorder, febrile seizure, Methylphenidate, Adverse effect, Adolescent

JOURNAL FREE ACCESS

2020 Volume 11 Pages 51-53

DOI https://doi.org/10.5234/cnpt.11.51

Details

Abstract

Methylphenidate (MPH) is the main psychostimulant drug for children and adolescents with ADHD. The long-acting stimulant of osmotic controlled-release oral delivery system (OROS) MPH has been designed to release gradually increasing concentrations of MPH over a period of 10-12 hours. Febrile seizure (FS) is a seizure associated with high body temperature, typically due to a viral infection. In this case report, a 17-year-old boy with a history of ADHD who experienced a febrile seizure while taking OROS-MPH is reported.

Content from these authors

Favorites & Alerts

Corresponding author

Register with J-STAGE for free!